HARD Reddit Mentions | ChartExchange

My AI Slop Analysis:
**BLGO -- BioLargo, Inc.**

\## One-liner verdict

Nineteen years public, never a profit, barely two months of cash left, and a customer who built an empire on their chemistry and then stole it — HARD AVOID.

BioLargo has been publicly traded since 2007 and has never once turned a fucking profit. The stock is at $0.08 right now — not near its fifty-two-week low but literally on it, the exact low set August 20, 2026. It was forty cents in February 2024. That eighty-percent collapse happened while management filed press release after press release about PFAS remediation breakthroughs, wound care devices, and battery storage partnerships. The science may be real. The business has not figured out how to make money from any of it across nineteen years.

The fastest way to understand what happened to the revenue is Pooph. Pooph Inc. was a pet-odor brand that licensed BioLargo's chemistry, became their single biggest customer, and drove quarterly revenue to $2.777 million in Q2 2025. Then Pooph stopped paying royalties in August 2025, quietly developed a replacement formula the whole time, terminated the agreement, walked off with the brand, and left BioLargo holding $3.763 million in unpaid receivables — $1.378 million in royalties and $2.385 million in product invoices — for which BioLargo established a full credit loss provision (10-Q, EDGAR 0001437749-26-028023). Some bastard built a pet-odor empire on BioLargo's work, reverse-engineered their way out of it, and ghosted a three-million-dollar bill. Q2 2026 revenue: $1.248 million. That is a fifty-five percent year-over-year collapse.

There are no confirmed near-term catalysts that change the math here, and that is worth saying plainly — there is not a goddamn hard-dated event in the next sixty days. Management mentioned an October consumer relaunch at their September 10 town hall — their own microphone, their own audience, no signed contract, no named distribution partner, not backed by inventory on order. The PFAS engineering business is genuinely growing. It is growing off a small base while the parent company burns through cash at a pace that makes slow organic growth irrelevant. ALREADY PRICED IN at eight cents.

The cash emergency is happening right now. $2.188 million in the account at June 30, 2026, against operating burn of $5.973 million in the first half of the year — roughly $3 million per quarter. At that pace the cash is gone in approximately 2.2 months. They survived H1 by raising $4.469 million through warrant exercises and subsidiary capital raises. Here is where that shit stops: the April 2026 warrant prospectuses show exercise prices from $0.19 to $0.33, weighted average around $0.265 (424B4 filings, EDGAR, April 2026). Every outstanding warrant is dead at $0.08. A new equity offering is coming because the math demands one, and existing shareholders take the dilution.

The balance sheet is broken everywhere you look. Stockholders' equity is negative $1.852 million. Working capital is negative $1.266 million. Enterprise value at verified net debt runs to roughly $29 million — nearly six times the annualized quarterly revenue run rate of about $5 million. Expensive as shit for a company with negative equity, no working capital, and a cash account ticking toward zero. Share count is 328.7 million and only goes higher. Institutional ownership is 0.036 percent.

.dark-mode .TrY7fY{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .TrY7fY{ color: #333333; background-color: white; border: 2px solid #333333; }HARDSimplify Commodities Strategy No K-1 ETFstock NYSE ETF

HARD
Simplify Commodities Strategy No K-1 ETF
stock NYSE ETF